Up | AC Home Page

Joint Meeting of the Pulmonary-Allergy Drugs Advisory Committee, Drug Safety & Risk Management Advisory Committee, and the Pediatric Advisory Committee

December 10 & 11, 2008

 

 

BRIEFING INFORMATION  

 

FDA

 

Disclaimer  

Portions of this document have been determined to be exempt from disclosure under the Freedom of Information Act (the FOIA) (5 U.S.C. § 552).

 

FDA Briefing Material (pdf)

Errata (pdf)

 

Bibliography (pdf)  

 

Sponsors

 

Disclaimer  

The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.  

 

Novartis Pharmaceuticals Corporation (pdf)

 

AstraZeneca (pdf)

 

GlaxoSmithKline (pdf)

---